Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct001
Abstract: Background We report pivotal results from the registrational filing data cut-off (DCO) of the 200 mg dose used in the LINKER-MM1 (NCT03761108) clinical trial, testing the safety and efficacy of linvoseltamab (a B-cell maturation antigen… read more here.
Keywords: cell maturation; linvoseltamab; response; maturation antigen ... See more keywords
Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200109
Abstract: Introduction: B-cell maturation antigen (BCMA) is highly expressed on the surface of plasma cells from patients with multiple myeloma (MM). Linvoseltamab, a human bispecific antibody that is being developed for the treatment of relapsed/refractory MM… read more here.
Keywords: dose; exposure; linvoseltamab; response ... See more keywords